Background {#Sec1}
==========

Immunoglobulin A nephropathy (IgAN) is a common glomerulonephritic disease that is one of the major causes of end-stage renal disease (ESRD) \[[@CR1]\]. The prevalence of IgAN in male and female patients differs geographically. The ratios of male to female patients range from less than 2:1 in Asians to as high as 6:1 in Europe and the United States \[[@CR2]--[@CR4]\]. Poor prognostic factors for renal progression in IgAN have been identified, including hypertension, heavy proteinuria, and severe histopathological abnormalities \[[@CR5]--[@CR7]\]. However, the differences in renal progression between male and female IgAN patients are controversial. Several studies have found that renal progression occurs faster in males than in females \[[@CR5], [@CR8]\], whereas other studies have found either no gender differences \[[@CR9], [@CR10]\] or a greater risk of renal progression in females \[[@CR11]\]. The impact of gender on the progression of IgAN remains uncertain. Meanwhile, few studies have specifically described the associations between gender and renal outcomes \[[@CR8], [@CR12]\]. To better understand these associations in IgAN patients, we conducted a retrospective study of a large number of Chinese patients with biopsy-diagnosed primary IgAN.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

This was a single-centre retrospective study. All patients with biopsy-diagnosed primary IgAN who were recorded in the IgAN Database of The First Affiliated Hospital, Sun Yat-sen University from 1 January 2006 to 31 December 2011 were considered. The inclusion criteria were as follows: biopsy-diagnosed primary IgAN, age ≥ 14 years, adequate biopsy sample containing ≥10 glomeruli, and willingness to sign the informed consent form. Patients were excluded if they presented with secondary causes of mesangial IgA deposition (such as hepatitis B-related nephritis, Henoch-Schonlein purpura nephritis, lupus nephritis, transplantation-related IgAN, etc), ESRD \[estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73 m^2^\], or a follow-up duration \< 12 months. Patients who suffered from kidney stone, urological malignancies, or menstruating females were also excluded.

Data collection {#Sec4}
---------------

Demographic and clinicopathologic data were collected at biopsy. Clinical parameters included gender, age, blood pressure (BP), hypertension (defined as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg or requirement for anti-hypertensive therapy), haemoglobin, total protein, serum albumin, total cholesterol, triglycerides, hypercholesterolaemia (defined as serum total cholesterol ≥5.2 mmol/L), hypertriglyceridaemia (defined as serum triglycerides ≥1.7 mmol/L), serum uric acid (SUA), hyperuricaemia (defined as SUA \> 420 μmol/L in males, and \> 360 μmol/L in females), serum creatinine (Scr), blood urine nitrogen (BUN), eGFR (estimated using the Modification of Diet in Renal Disease (MDRD) equation) \[[@CR13]\], proteinuria (defined as 24-h urine protein excretion), gross haematuria (glomerular was distinguished from non-glomerular haematuria by examining urine sediment with a phase contrast microscope), microscopic haematuria (defined as \> 3 red blood cells in a high-power field on microscopic evaluation), and medication regimen.

Renal biopsy specimens were examined by light, immunofluorescence and electron microscopy (EM) and graded according to the Oxford classification system, which includes mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and tubular atrophy/interstitial fibrosis (T) \[[@CR14]\]. The pathological features also included global glomerulosclerosis, crescent formation, capillary loop necrosis, interstitial inflammation and vascular lesions. All renal biopsy results were reviewed independently by two renal pathologists.

Outcomes of interest {#Sec5}
--------------------

The primary endpoint was renal outcome comprising the doubling of baseline Scr and ESRD (eGFR\< 15 mL/min/1.73 m^2^, dialysis, or renal transplantation). The renal outcomes were collected from the time of biopsy to the end of the follow-up period.

Statistical analyses {#Sec6}
--------------------

Continuous data with a normal distribution were expressed as the mean ± SD and compared by independent sample t tests. Continuous data with a skewed distribution were expressed as the median (inter-quartile range, IQR) and were analysed by Wilcoxon rank sum tests. Categorical variables were summarized as frequencies and percentages, and comparisons were conducted using chi-squared tests. The cumulative renal survival rates were estimated by the Kaplan-Meier method, and the log-rank test was applied for comparisons. The variables affecting renal outcomes were identified by univariable and multivariable Cox proportional hazards models. The proportional hazard assumption was evaluated in each multivariable Cox model, and if violated, time-dependent covariates were used for adjustments. The results are expressed as a hazard ratio (HR) and 95% confidence interval (CI). Sensibility analyses were conducted using frequency matching for eGFR (\< 60.0, 60.0--89.9, and ≥90.0 mL/min/1.73 m^2^) and SUA levels (\< 316, 316--419, 420--524, 525--629, and ≥630 μmol/L for males; \< 271, 271--359, 360--449, 450--539, and ≥540 μmol/L for females) to balance significant differences between gender groups and then to evaluate the association of gender with renal survival. Due to inherent physical differences in SUA levels between genders, use of the same values to group both male and female patients could possibly exaggerate the clinical significance of SUA in the different genders. Therefore, we divided the patients into different SUA groups based on the normal SUA levels of the two genders. The group intervals were equal to one-fourth of the normal SUA levels in the two genders: 105 μmol/L in males and 90 μmol/L in females. All *P*-values were two-tailed, and a value \< 0.05 was considered statistically significant. Data analysis was performed using SPSS (version 13; SPSS Inc., Chicago, IL).

Results {#Sec7}
=======

Clinicopathological features of IgAN patients {#Sec8}
---------------------------------------------

A total of 988 IgAN patients were analysed in this study. The ratio of males to females was 1:1.4, with a median age of 32 (26, 39) years at biopsy. The results of comparisons of clinical and histological parameters between male and female patients are summarized in Table [1](#Tab1){ref-type="table"}. Compared with female patients, male IgAN patients exhibited more severe clinical manifestations, including higher levels of serum creatinine, BUN and SUA; a lower eGFR; heavier proteinuria; and higher proportions of hypertension, hypertriglyceridaemia and hyperuricaemia (*P* \< 0.05). In female patients, the most common renal manifestation was haematuria, including a higher frequency of gross haematuria and more severe microscopic haematuria (*P* \< 0.01). Additionally, male patients had worse histological lesions, including more S, T and interstitial inflammation (*P* \< 0.05). There were no differences in the proportion of global glomerulosclerosis, crescent formation, or the degree of M and E lesions between male and female patients (*P \>* 0.05). No significant differences were observed in the use of ACEi/ARB, corticosteroids or immunosuppressive agents between the genders. The frequency of allopurinol usage was higher in males than in females (10.7% vs. 1.8%).Table 1Clinicopathologic characteristics of IgAN patients of different gendersVariableTotal (*n* = 988)Males (*n* = 417)Females (*n* = 571)*P-*valueAge (years)32 (26, 39)31 (24, 38)32 (27, 39)0.003Systolic blood pressure (mmHg)123 (112, 136)128 (119, 140)119 (110, 133)\< 0.001Diastolic blood pressure (mmHg)79 (70, 88)80 (71, 89)78 (70, 87)\< 0.001Hypertension (n \[%\])331 (33.5)168 (40.3)163 (28.5)\< 0.001Proteinuria (g/d)0.58 (0.30, 1.21)0.69 (0.33, 1.47)0.53 (0.27, 1.05)\< 0.001Microscopic haematuria (n \[%\])0.006\<++590 (60.0)271 (65.1)319 (56.3)≥++393 (40.0)145 (34.9)248 (43.7)Gross haematuria (n \[%\])280 (28.3)82 (19.7)198 (34.7)\< 0.001Haemoglobin (g/L)127.0 (115.0, 140.0)139.0 (128.0, 151.0)121.0 (111.0, 129.0)\< 0.001Total protein (g/L)67.0 (61.0, 71.0)67.0 (62.0, 72.0)66.0 (61.0, 71.0)0.613Albumin (g/L)40.0 (36.5, 42.9)41.0 (37.4, 43.0)39.0 (36.0, 42.0)\< 0.001Cholesterol (mmol/L)4.97 (4.2, 5.9)4.9 (4.2, 5.9)5.0 (4.3, 5.9)0.932Hypercholesterolaemia (n \[%\])397 (42.0)168 (41.7)229 (42.3)0.894Triglycerides (mmol/L)1.25 (0.87, 1.90)1.39 (0.98, 2.00)1.15 (0.77, 1.81)\< 0.001Hypertriglyceridaemia (n \[%\])282 (29.8)136 (33.7)146 (26.9)0.026SUA (μmol/L)348 (269, 429)405 (343, 492)295 (239, 373)\< 0.001Hyperuricaemia (n \[%\])322 (34.7)174 (43.9)148 (27.9)\< 0.001Scr (mmol/L)80.0 (61.0, 116.5)102.0 (81.0, 161)64.0 (55.0, 89.0)\< 0.001BUN (mmol/L)5.4 (4.4, 7.2)6.2 (4.8, 8.1)4.9 (4.1, 6.3)\< 0.001eGFR (mL/min/1.73 m^2^)95.5 (59.9, 123.2)80.8 (42.9.1, 107.4)111.3 (71.9, 133.7)\< 0.001Mean proportion of global glomerulosclerosis (%)11.1 (0.0, 30.8)13.3 (0.0, 35.7)10.0 (0.0, 27.8)0.205Crescent (n \[%\])434 (43.9)195 (46.8)239 (41.9)0.136Mesangial hypercellularity (M1) (n \[%\])524 (54.0)225 (55.3)299 (53.1)0.514Endocapillary hypercellularity (E1) (n \[%\])193 (20.4)77 (19.4)116 (21.1)0.568Segmental sclerosis (S1) (n \[%\])447 (46.3)204 (50.4)243 (43.3)0.031Tubular atrophy/interstitial fibrosis (T) (n \[%\])0.001T0711 (73.5)273 (67.4)438 (77.9)T1227 (23.5)119 (29.4)108 (19.2)T229 (3.0)13 (3.2)16 (2.8)Interstitial inflammation (n \[%\])0.020None\~mild818 (82.8)329 (78.9)489 (85.6)Moderate151 (15.3)79 (18.9)72 (12.6)Severe19 (1.9)9 (2.2)10 (1.8)ACEi/ARB (n \[%\])781 (79.4)335 (80.9)446 (78.2)0.338Corticosteroids (n \[%\])293 (29.8)137 (33.1)156 (27.4)0.057Immunosuppressive agents (n \[%\])22 (2.3)11 (2.7)11 (2.0)0.515Allopurinol (n \[%\])54 (5.5)44 (10.7)10 (1.8)\<0.001Continuous variables: mean ± SD; Continuous skewed variables: median (interquartile range); Categorical variables: frequency (percentage)*SUA* serum uric acid, *Scr* serum creatinine, *eGFR* estimated glomerular filtration rate, *BUN* blood urea nitrogen, *ACEI* angiotensin converting enzyme inhibitor, *ARB* angiotensin II receptor blockerACEi/ARB indicates exposure to ACEI, ARB, or both. Immunosuppressive agents included MMF, CTX, CsA, and FK506

Renal survival of IgAN patients according to gender {#Sec9}
---------------------------------------------------

After a median follow-up period of 48.6 (34.7, 62.7) months, 107 (10.8%) patients (48.6% male vs 51.4% female) reached renal outcomes. A total of 16 (1.6%) patients achieved doubling of Scr, and 91 (9.2%) patients developed ESRD. Kaplan-Meier curves showed that the renal survival rates calculated from the combined events at 3, 5, and 7 years were 92.9%, 84.3%, and 73.1% in males and 95.6%, 89.4%, and 75.8% in females, respectively. No significant difference was observed in cumulative renal survival rates between male and female IgAN patients (log-rank test *P* = 0.090) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Renal survival curves of male and female IgAN patients. No significant difference was observed in the renal survival rate of combined events (doubling of baseline Scr and ESRD) between the different genders of IgAN patients

Univariate analysis showed no significant differences in renal outcomes between males and females (HR: 1.39, *P* = 0.091). Next, we constructed multivariable Cox models of gender adjusted for clinical factors and pathologic features, but no significant differences in renal outcomes between male and female IgAN patients were observed after adjustments for age and hypertension in Model 1 (HR: 1.12, *P* = 0.584), after adding pathologic features (proportions of global glomerulosclerosis, degrees of S and T lesions) in Model 2 (HR: 0.95, *P* = 0.824), or after adding pathologic features and clinical parameters (albumin and proteinuria) in Model 3 (HR: 0.97, *P* = 0.876). However, male gender was shown to be a protective factor when fully adjusting for eGFR and the SUA level in Model 4 (HR: 0.59, *P* = 0.029) (Table [2](#Tab2){ref-type="table"}).Table 2The association of gender with renal survival by Cox regression analysis before and after frequency matching of SUA levels and eGFRModelHazard ratios (95% CI)*P-*valueBefore matching Univariate1.39 (0.95, 2.03)0.091 Model 1: age, hypertension1.12 (0.76, 1.65)0.584 Model 2: Model 1+ proportion of global glomerulosclerosis, S1, T1, T20.95 (0.62, 1.46)0.824 Model 3: Model 2 + Albumin, Proteinuria0.97 (0.62, 1.50)0.876 Model 4: Model 3 + eGFR, SUA0.59 (0.36, 0.95)0.029After matching Univariate0.75 (0.48,1.18)0.220 Model 1: age, hypertension0.62 (0.39,1.00)0.052 Model 2: Model 1 + proportion of global glomerulosclerosis, S1, T1, T20.73 (0.43,1.24)0.248 Model 3: Model 2+ Proteinuria0.72 (0.42,1.23)0.230*CI* confidence interval, *eGFR* estimated glomerular filtration rate, *SUA* serum uric acid, *S* segmental sclerosis, *T* tubular atrophy/interstitial fibrosis

Significant differences were found in the SUA level and eGFR between female and male patients (*P* \< 0.001). To eliminate biases due to significant intergroup differences, we conducted sensibility analyses by frequency matching the eGFR (\< 60.0, 60.0--89.9, and ≥90.0 mL/min/1.73 m^2^) and SUA levels (\< 316, 316--419, 420--524, 525--629, and ≥630 μmol/L for males; \< 271, 271--359, 360--449, 450--539, and ≥540 μmol/L for females) between male and female groups and then evaluating the association between gender and renal survival. As shown in Table [3](#Tab3){ref-type="table"}, after controlling for these confounding factors (baseline eGFR and SUA) by frequency matching, no significant difference was observed in long-term renal survival between male and female IgAN patients (HR: 0.72, *P* = 0.230) (Table [2](#Tab2){ref-type="table"}).Table 3Distribution of eGFR and SUA levels before and after frequency matching in the current studyVariablesMalesFemales*P-*valuen = 417n = 571Before matching\
(n = 988)eGFR (mL/min/1.73 m^2^)80.8 (42.9, 107.4)111.3 (71.9, 133.7)\< 0.001eGFR group (n\[%\])\< 60.0139 (33.3)\< 60.095 (16.6)\< 0.00160.0--89.9112 (26.9)60.0--89.998 (17.2)≥90.0166 (39.8)≥90.0378 (66.2)SUA (μmol/L)405 (343, 492)295 (239, 373)\< 0.001SUA group (n\[%\])\< 31677 (19.4)\< 271214 (40.3)\< 0.001316--419145 (36.6)271--359166 (31.3)420--524100 (25.3)360--44999 (18.6)525--62956 (14.1)450--53936 (6.8)≥63018 (4.5)≥54016 (3.0)Hyperuricaemia (n \[%\])174 (43.9)148 (27.9)\< 0.001After matching\
(*n* = 678)*n* = 329*n* = 349eGFR (mL/min/1.73 m^2^)88.8 (59.0, 115.3)91.1 (61.0, 118.2)0.353eGFR group (n \[%\])\< 60.084 (25.5)\<60.083 (23.8)0.81260.0--89.983 (25.2)60.0--89.986 (24.6)≥90.0162 (49.2)≥90.0180 (51.6)SUA (μmol/L)400.0 (332.0, 469.0)328.0 (289.0, 404.0)\< 0.001SUA group (n \[%\])\< 31667 (21.3)\< 27159 (17.8)0.601316--419118 (37.5)271--359143 (43.2)420--52488 (27.9)360--44986 (26.0)525--62933 (10.5)450--53932 (9.7)≥6309 (2.9)≥54011 (3.2)Hyperuricaemia (n \[%\])130 (41.3)126 (38.1)0.422*eGFR* estimated glomerular filtration rate, *SUA* serum uric acidSUA group intervals were equal to one-fourth of the normal SUA levels of the different genders

In addition, to identify the associated risk factors of composite renal outcomes (doubling of baseline Scr and ESRD) in males and females with IgAN, univariate and multivariate analyses were performed. As shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, Cox regression analysis revealed similar risk factors in male and female IgAN patients, including low eGFR, high levels of proteinuria and increased S1 lesions (*P* \< 0.05). However, an increased proportion of global glomerulosclerosis was significant only in male patients (HR: 1.02, *P* = 0.028).Table 4Associated risk factors of renal survival in male patientsUnivariateMultivariateVariablesHR (95% CI)*P-*valueHR (95% CI)*P-*valueAge (per 1-year increase)1.00 (0.98, 1.03)0.8800.97 (0.94, 1.01)0.139Hypertension (vs. no)2.43 (1.40, 4.23)0.0020.62 (0.32, 1.19)0.150Proteinuria (1 g/d increase)1.28 (1.14, 1.43)\< 0.0011.22 (1.02, 1.46)0.032eGFR (1 mL/min/1.73 m^2^ increase)0.95 (0.94, 0.96)\< 0.0010.95 (0.94, 0.97)\< 0.001Proportion of global glomerulosclerosis (1% increase)1.05 (1.04, 1.06)\< 0.0011.02 (1.00, 1.04)0.028S1 (vs. S0)3.60 (1.95, 6.61)\< 0.0013.11 (1.49, 6.47)0.002T1 (vs. T0)8.47 (4.25, 16.90)\< 0.0010.83 (0.30, 2.28)0.718T2 (vs. T0)41.65 (15.38, 112.79)\< 0.0011.89 (0.50, 7.24)0.351*HR* hazard ratio, *CI* confidence interval, *eGFR* estimated glomerular filtration rate, *S* segmental sclerosis, *T* tubular atrophy/interstitial fibrosisTable 5Associated risk factors of renal survival in female patientsUnivariateMultivariateVariableHR (95% CI)*P-*valueHR (95% CI)*P-*valueAge (per 1-year increase)0.99 (0.97, 1.02)0.6311.13 (0.92, 1.40)0.242Hypertension (vs. no)4.85 (2.81, 8.36)\< 0.0011.76 (0.85, 3.62)0.126Proteinuria (1 g/d increase)1.76 (1.52, 2.04)\< 0.0011.26 (1.03, 1.54)0.023eGFR (1 mL/min/1.73 m^2^ increase)0.96 (0.95, 0.97)\< 0.0010.98 (0.96, 0.99)\< 0.001Proportion of global glomerulosclerosis (1% increase)1.05 (1.04, 1.06)\< 0.0011.10 (1.00, 1.21)0.058S1 (vs. S0)4.93 (2.69, 9.02)\< 0.0012.36 (1.42, 5.45)0.012T1 (vs. T0)10.81 (5.75, 20.33)\< 0.0011.75 (0.80, 3.81)0.162T2 (vs. T0)31.43 (13.53, 73.02)\< 0.0011.76 (0.58, 5.30)0.318*HR* hazard ratio, *CI* confidence interval, *eGFR* estimated glomerular filtration rate, *S* segmental sclerosis, *T* tubular atrophy/interstitial fibrosis

Discussion {#Sec10}
==========

To date, only a few studies have evaluated differences in clinicopathologic features and the prognosis of IgAN between the different genders. In this study, we found that male IgAN patients presented with worse clinicopathological features than female patients. However, no significant difference was observed in long-term renal survival between male and female patients after frequency matching of baseline eGFR and SUA levels. In addition, we found that male and female patients shared similar risk factors, including low eGFR, heavy proteinuria and extensive segmental sclerosis, but the proportion of global glomerulosclerosis was a significant risk factor only in male patients.

According to our study, approximately 58.3% of the patients diagnosed with IgAN were females. The gender distribution of IgAN in China is similar to that in other nations in East Asia, with a male to female ratio of less than 2:1 \[[@CR9], [@CR15], [@CR16]\], but it is different from that in Northern Europe and the United States, with a ratio as high as 6:1 \[[@CR11], [@CR17]\]. Variations in the gender distribution of IgAN may reflect differences in biopsy indications in different regions and could also be due to the diversity of genetic backgrounds.

In the clinicopathologic baseline data, we noticed the relatively worse condition of the male patients compared with the female patients, which is similar to previous reports. A study by Cattran DC et al. reported a higher mean arterial pressure (MAP) and lower corrected creatinine clearance (CrCl) in males than in females with IgAN \[[@CR10]\]. In another study, Eiro et al. indicated that male gender was positively correlated with hypertension \[[@CR18]\]. However, Tanaka K et al. more frequently observed a high level of urinary red blood cells (≥20/HPF) in female patients \[[@CR19]\]. Our study not only confirmed these results but also found that male IgAN patients exhibited greater urinary protein excretion. In addition, we found that severe renal histological injury occurred even in male patients, including increased S, T and interstitial inflammation, which may be predictors of renal progression in IgAN. These findings suggest that male patients with IgAN disease, which was mainly mediated through worse clinicopathological characteristics, may have poorer renal outcomes.

However, the impact of gender on the progression of IgAN remains under debate. In a study by Goto M, male gender, rather than female gender, was associated with the risk of ESRD \[[@CR5]\]. In addition, according to correlation analysis of the main prognostic risk factors affecting the progression of IgAN, Riispere Ž et al. concluded that IgA nephropathy progressed more rapidly in males compared with females \[[@CR8]\]. The possible mechanisms underlying the renal protective role of female gender seem to be related to oestrogen \[[@CR12]\]. However, other investigators have found either no gender-related differences or have observed women to be at a greater risk of a progressive loss of renal function. Donadio JV et al. reported contrary results for IgAN in female patients, pointing to worse disease outcomes \[[@CR11]\]. Furthermore, a study performed by Cattran DC et al. showed no significant difference in long-term renal survival in IgAN between the different genders \[[@CR10]\].

To our surprise, in our study, male gender predicted poorer outcomes in multivariable analysis, but male gender lost its prognostic value after frequency matching of baseline eGFR and SUA levels. The reason for this finding may be the possible confounding effects of baseline factors. Significant differences were observed in baseline eGFR and SUA levels between female and male patients. As shown in Table [1](#Tab1){ref-type="table"}, a low eGFR and a high SUA level were more frequently observed in males than in females (*P* \< 0.001). The major confounding factors in our study were imbalances in baseline eGFR and SUA levels. To control for the confounding effect of renal function on the association between gender and progression, eGFR- and Scr-matched and frequency matching analyses were performed. After frequency matching of clinically relevant factors, including eGFR and SUA levels, which are associated with renal outcomes, the gender difference lost its significance in multivariate analysis. Therefore, the potential risk effect of gender on renal outcomes may be due to these gender differences in the association between the eGFR and SUA levels and the progression of IgAN. The MDRD study showed slower renal disease progression in glomerular filtration rate (GFR) in women, as well as a significantly slower rate of GFR decline in women than in men \[[@CR20], [@CR21]\]. In general, women have lower average rates of creatinine generation, due to lower muscle mass and meat intake. Similarly, the SUA concentration increases with age and is physiologically higher in males than age-matched females \[[@CR22]\]. The study by Nagasawa Y et al. indicated a gender difference with respect to the effects of uric acid on the progression of uric acid-induced kidney disease \[[@CR23]\]. The mechanism of this gender difference in the association between the SUA level and the progression of IgAN remains unclear. Oestrogen suppresses the protein levels of the urate reabsorptive transporter (urate transporter1; URAT1) in the kidney, which results in an increase in uric acid excretion and a decrease in the uric acid level in the serum \[[@CR24]\]. Moreover, Kolz et al. have found that the minor allele for rs734553 in SLC2A9 has a greater influence on reducing SUA levels in females and that the minor allele of rs2231142 in ABCG2 increases SUA levels more strongly in males compared with females \[[@CR25]\].

Proteinuria, hypertension and renal function are important risk factors for IgAN \[[@CR5], [@CR7], [@CR9], [@CR16]\]. In addition, the proportions of glomerular glomerulosclerosis and S were critical predictors of poor prognosis of IgAN \[[@CR14], [@CR26], [@CR27]\]. As expected, we confirmed that a low eGFR, heavy proteinuria and increased S were significantly associated with an increased risk in both male and female patients. Generally, no significant differences were observed in the associated risk factors or renal outcomes relative to gender in IgAN patients.

This study has several limitations. First, this was a single-centre retrospective study, with a median follow-up time of 48.6 (34.7, 62.7) months, therefore, we will continue to follow up with these patients. The current follow-up time was not long enough compared with the development of the disease. Second, treatment may play a role in the prognosis of IgAN, but the effects of therapeutic interventions could not be considered. Therapeutic regimes were flexible according to the physicians' clinical decision making, and immunosuppression, in particular, was not standardized; thus, such unadjusted confounding impairs data interpretation. Therefore, further well-designed, multicentre, large cohort studies with longer, regular follow-ups are necessary to confirm these findings.

Conclusions {#Sec11}
===========

In summary, our findings suggested that male IgAN patients presented with worse clinicopathological changes than female patients, but when we controlled for the confounding effect of renal function by eGFR- and Scr-matching using frequency matching analyses, no significant difference in long-term renal survival was observed between male and female patients.
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